EpiPen price hike under Congressional scrutiny
The maker of EpiPen, a potentially life-saving medical device for severe allergic reactions, is now under Congressional scrutiny over how its cost has risen nearly 500 percent since 2009. But one prominent and controversial figure, former pharma CEO Martin Shkreli who has no connections to the EpiPen product, is defending the increase. Vinita Nair reports.